Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Holding(s) in Company

9 May 2025 08:24

RNS Number : 0549I
N4 Pharma PLC
09 May 2025
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

N4 Pharma Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii: Dematerialisation of holding into Fiske Nominees Limited

x

3. Details of person subject to the notification obligation iv

Name

Tracarta Limited

City and country of registered office (if applicable)

OMC Chambers, Wickhams Cay 1, Road Town, Tortola, British Virgin Islands

4. Full name of shareholder(s) (if different from 3.) v

Name

Fiske Nominees Limited

City and country of registered office (if applicable)

100 Wood Street, London, England, EC2V 7AN

5. Date on which the threshold was crossed or reached vi:

01/05/2025

6. Date on which issuer notified (DD/MM/YYYY):

08/05/2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

18.02

-

18.02

150,000,000

Position of previous notification (if

applicable)

18.02

-

18.02

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYW8QM32

  150,000,000

-

18.02

-

SUBTOTAL 8. A

150,000,000

18.02

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Tracarta Limited

18.02

-

18.02

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

St. Peter Port, Guernsey

Date of completion

08/05/2025

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFIFFDEVIAIIE
Date   Source Headline
17th Mar 202612:14 pmRNSResult of General Meeting and Change of Name
27th Feb 20267:00 amRNSNotice of GM and Proposed Change of Name
24th Feb 20267:00 amRNSCEO Appointment & Name Change Thalia Therapeutics
17th Dec 20257:00 amRNSBusiness and Operational Update
25th Sep 20257:00 amRNSInterim Results
23rd Sep 20257:00 amRNSPartnership with University of Strathclyde’s CMAC
22nd Sep 20257:00 amRNSN4 Pharma’s Nuvec® Targets Lung Cancer Cells
19th Sep 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
11th Sep 20257:00 amRNS-RInvestor Event and Presentation
30th Jul 20251:55 pmRNS-RArticle on Nuvec®’s Potential in RNA Therapeutics
14th Jul 20257:00 amRNS-RInvestor Webinar
8th Jul 20257:00 amRNSDirectorate Change
30th Jun 20252:15 pmRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
25th Jun 20257:00 amRNS-RInsight Event for Retail Investors
6th Jun 20257:00 amRNSFinal Results, Annual Report and Notice of AGM
27th May 20257:00 amRNS-REstablishment of New Senior Leadership Team
23rd May 202512:37 pmRNSTR-1: Notification of major holdings
21st May 20254:11 pmRNSHolding(s) in Company
15th May 20253:13 pmRNSChange of Registered Address
12th May 20257:00 amRNSN4 101 In Vivo Study Results
9th May 20258:24 amRNSHolding(s) in Company
29th Apr 20254:25 pmRNSHolding(s) in Company
29th Apr 202511:05 amRNSHolding(s) in Company
28th Apr 20252:30 pmRNSHolding(s) in Company
23rd Apr 20252:32 pmRNSTR-1: Standard form notification of major holdings
22nd Apr 202511:56 amRNSResult of General Meeting
4th Apr 20257:08 amRNSPosting of Circular and Notice of General Meeting
1st Apr 20254:08 pmRNSPlacing and Subscription to raise £1,750,000
18th Feb 202512:34 pmRNSHolding(s) in Company
7th Feb 20257:00 amRNS-RInvestor Webinar
27th Jan 20257:00 amRNS-RInvestor Webinar
16th Jan 20257:00 amRNS-RN4 Pharma Non-Executive Director Q&A
8th Jan 20257:00 amRNSDirectorate Changes
12th Dec 20247:00 amRNSN4 101 In Vitro Results
4th Dec 20247:00 amRNSNew Patent Filing
28th Nov 20247:00 amRNSGrant of Options
24th Sep 20247:00 amRNSInterim Results
17th Sep 20248:04 amRNSSRI Research Update
9th Sep 20247:00 amRNSDirector Appointment
23rd Aug 20248:30 amRNSChange of Auditor
20th Aug 20247:00 amRNSSRI Research Update
3rd Jul 20247:00 amRNSNanogenics Update
28th Jun 20247:00 amRNSTotal Voting Rights
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 202412:34 pmRNSHolding(s) in Company
13th Jun 20244:52 pmRNSHolding(s) in Company
11th Jun 202411:16 amRNSNew Corporate Presentation
7th Jun 202410:18 amRNSPlacing and Subscription to raise £630,000
23rd May 20244:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.